Acción JMACU MAXPRO CAPITAL ACQUISITION CORP.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Maxpro Capital Acquisition Corp. Nasdaq

Acciones

JMACU

US57778T2050

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Maxpro Capital Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Apollomics Announces Completion of Business Combination and Listing on Nasdaq
Maxpro Capital Acquisition Corp.(NasdaqGM:JMAC) dropped from NASDAQ Composite Index
Apollomics, Inc. completed the acquisition of Maxpro Capital Acquisition Corp. from MP One Investment LLC and others in a reverse merger.
MAXPRO CAPITAL ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination
Maxpro Capital Acquisition Extends Deadline to Complete Business Combination
MAXPRO CAPITAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Maxpro Capital Acquisition Corp. announced that it has received $0.5 million in funding from MP One Investment LLC
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations
Apollomics Gets Orphan Drug Designation for Vebreltinib to Treat Lung Cancer
MAXPRO CAPITAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Maxpro Capital Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination
MAXPRO CAPITAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción JMAC
  4. Acción JMACU
  5. Noticias Maxpro Capital Acquisition Corp.
  6. Otros idiomas